Technology area: Biotechnology & Pharmaceuticals
8 pending office actions • 5 art units • 6 examiners • 0 of 8 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
Fate Therapeutics Inc. has 10 pending office actions in Biotechnology & Pharmaceuticals. The matters involve 8 distinct examiners and 6 distinct art units, creating a broad prosecution footprint with multiple examination channels.
ZHU, JIANJIAN is the busiest examiner, with 3 pending matters. That assignment provides a meaningful point for coordinated review, while the remaining matters require separate tracking across the other examiners and art units.
Counsel should organize portfolio management by both technical subject and examination assignment. Shared biotechnology and pharmaceutical terminology can support consistency, but each action should receive an independent assessment of claim scope, prior art, and amendment consequences.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 2 (25%) |
| §112 only | 1 (12%) |
| Double-patenting + other | 2 (25%) |
| Multi-statute (no §101) | 3 (38%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ZHU, JIANJIAN | 3 | 58.1% | +82.5% |
| FAUST, AMBER KATHLEEN | 1 | 61.1% | +53.6% |
| SZPERKA, MICHAEL EDWARD | 1 | 62.6% | +37.5% |
| STOICA, ELLY GERALD | 1 | 66.8% | +22.6% |
| NATARAJAN, MEERA | 1 | 62.6% | +17.9% |
| WESTON, ALYSSA G | 1 | 59.5% | +49.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17782600 | ENHANCEMENT OF iPSC-DERIVED EFFECTOR IMMUNE CELL USING SMALL COMPOUNDS | WESTON, ALYSSA G | 30d overdue |
| 18441709 | COMPOSITIONS AND METHODS FOR IMMUNE CELL MODULATION IN ADOPTIVE IMMUNOTHERAPIES | ZHU, JIANJIAN | — |
| 17627574 | IMMUNE EFFECTOR CELL ENGINEERING AND USE THEREOF | NATARAJAN, MEERA | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17782600 | ENHANCEMENT OF iPSC-DERIVED EFFECTOR IMMUNE CELL USING SMALL COMPOUNDS | WESTON, ALYSSA G | 30d overdue |
| 18917836 | EFFECTOR CELLS AND USE THEREOF FOR ALLOGENEIC ADOPTIVE CELL THERAPIES IN SOLID TUMORS | FAUST, AMBER KATHLEEN | — |
| 18441709 | COMPOSITIONS AND METHODS FOR IMMUNE CELL MODULATION IN ADOPTIVE IMMUNOTHERAPIES | ZHU, JIANJIAN | — |
| 18250733 | ENGINEERED IPSC AND PERSISTENT IMMUNE EFFECTOR CELLS | SZPERKA, MICHAEL EDWARD | — |
| 18250737 | MULTIPLEXED ENGINEERED IPSCS AND IMMUNE EFFECTOR CELLS TARGETING SOLID TUMORS | STOICA, ELLY GERALD | — |
| 17627574 | IMMUNE EFFECTOR CELL ENGINEERING AND USE THEREOF | NATARAJAN, MEERA | — |
| 17769651 | ENHANCED CHIMERIC ANTIGEN RECEPTOR FOR IMMUNE EFFECTOR CELL ENGINEERING AND USE THEREOF | ZHU, JIANJIAN | — |
| 17766513 | ENHANCED CHIMERIC ANTIGEN RECEPTOR FOR IMMUNE EFFECTOR CELL ENGINEERING AND USE THEREOF | ZHU, JIANJIAN | — |
| Art Unit | Apps |
|---|---|
| 1631 | 3 |
| 1643 | 2 |
| 1641 | 1 |
| 1647 | 1 |
| 1633 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18917836 | EFFECTOR CELLS AND USE THEREOF FOR ALLOGENEIC ADOPTIVE CELL THERAPIES IN SOLID TUMORS | FAUST, AMBER KATHLEEN | 1643 | §103 | Final Rejection | — | Pending | Oct 16, 2024 |
| 18441709 | COMPOSITIONS AND METHODS FOR IMMUNE CELL MODULATION IN ADOPTIVE IMMUNOTHERAPIES | ZHU, JIANJIAN | 1631 | §102§103 | Non-Final OA | — | Pending | Feb 14, 2024 |
| 18250733 | ENGINEERED IPSC AND PERSISTENT IMMUNE EFFECTOR CELLS | SZPERKA, MICHAEL EDWARD | 1641 | §102§112DP | Non-Final OA | — | Pending | Apr 26, 2023 |
| 18250737 | MULTIPLEXED ENGINEERED IPSCS AND IMMUNE EFFECTOR CELLS TARGETING SOLID TUMORS | STOICA, ELLY GERALD | 1647 | §112 | Non-Final OA | — | Pending | Apr 26, 2023 |
| 17627574 | IMMUNE EFFECTOR CELL ENGINEERING AND USE THEREOF | NATARAJAN, MEERA | 1643 | §103§112 | Non-Final OA | — | Pending | Jul 25, 2022 |
| 17782600 | ENHANCEMENT OF iPSC-DERIVED EFFECTOR IMMUNE CELL USING SMALL COMPOUNDS | WESTON, ALYSSA G | 1633 | §102§103 | Non-Final OA | 30d overdue | Pending | Jun 03, 2022 |
| 17769651 | ENHANCED CHIMERIC ANTIGEN RECEPTOR FOR IMMUNE EFFECTOR CELL ENGINEERING AND USE THEREOF | ZHU, JIANJIAN | 1631 | §103DP | Final Rejection | — | Pending | Apr 15, 2022 |
| 17766513 | ENHANCED CHIMERIC ANTIGEN RECEPTOR FOR IMMUNE EFFECTOR CELL ENGINEERING AND USE THEREOF | ZHU, JIANJIAN | 1631 | §103Other | Final Rejection | — | Pending | Apr 04, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialFate Therapeutics Inc. has 8 pending office actions as of October 2026, spread across 5 art units and 6 examiners.
Jianjian Zhu has the most, with 3 of Fate Therapeutics Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
